Cargando…

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study

Background: The combination of antitumor necrosis factor-alpha (TNF-α) agents with immunomodulators (IMMs) is a common treatment for pediatric Crohn’s disease (CD). Although methotrexate (MTX) can be a first-line medication as an IMM, most clinicians in real-life practice, especially in South Korea,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yoon-Zi, Kang, Ben, Kim, Eun-Sil, Kwon, Yiyoung, Choe, Yon-Ho, Kim, Mi-Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526834/ https://www.ncbi.nlm.nih.gov/pubmed/37761016 http://dx.doi.org/10.3390/biomedicines11092575

Ejemplares similares

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

Upper gastrointestinal tract involvement is more prevalent in Korean patients with pediatric Crohn’s disease than in European patients
por: Kim, Eun Sil, et al.
Publicado: (2020)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients
por: Kim, Eun Sil, et al.
Publicado: (2022)

Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
por: Kwon, Yiyoung, et al.
Publicado: (2022)

COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesity
por: Kim, Eun Sil, et al.
Publicado: (2021)

Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
por: Choi, Sujin, et al.
Publicado: (2022)

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up
por: Lee, Yun Seok, et al.
Publicado: (2012)

Author Correction: COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesity
por: Kim, Eun Sil, et al.
Publicado: (2021)

How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
por: Kwon, Yiyoung, et al.
Publicado: (2022)

The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn’s Disease
por: Ha, Changhee, et al.
Publicado: (2020)

Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia
por: Kwon, Yiyoung, et al.
Publicado: (2021)

Impact of the histologic grade of acute gastrointestinal graft-versus-host disease on outcomes in pediatric patients treated with allogeneic hematopoietic stem cell transplantation
por: Kim, Eun Sil, et al.
Publicado: (2023)

Individual approach for treatment of primary intestinal lymphangiectasia in children: single-center experience and review of the literature
por: Kwon, Yiyoung, et al.
Publicado: (2021)

Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
por: Choi, Jaeyoung, et al.
Publicado: (2018)

Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy
por: Kim, Mi Jin, et al.
Publicado: (2015)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
por: Kim, Eun Sil, et al.
Publicado: (2023)

Increased monocyte abundance as a marker for relapse after discontinuation of biologics in inflammatory bowel disease with deep remission
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
por: Kim, Eun Sil, et al.
Publicado: (2021)

Change in the treatment strategy for pediatric Crohn's disease
por: Kim, Mi Jin, et al.
Publicado: (2010)

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
por: Lee, Hae Chan, et al.
Publicado: (2023)

Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
por: Kim, Mi Jin, et al.
Publicado: (2021)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

Clinical Course of Infliximab Treatment in Korean Pediatric Ulcerative Colitis Patients: A Single Center Experience
por: Kim, Jong Min, et al.
Publicado: (2014)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Needs for Increased Awareness of Gastrointestinal Manifestations in Patients With Human Inborn Errors of Immunity
por: Kim, Eun Sil, et al.
Publicado: (2021)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
por: Kim, Mi Jin, et al.
Publicado: (2021)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
por: Park, Sowon, et al.
Publicado: (2022)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
por: Kim, You Lim, et al.
Publicado: (2014)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
por: Aginbay, Aibar, et al.
Publicado: (2022)

Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
por: Jung, Jae Hoon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rieuo9p1706ske2013g170lbvj